Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1893 in Advanced CLDN6-positive Solid Tumors
NCT06681870Phase 1Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Dec 2024
- Primary completion
- Mar 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of ASP1893 in solid tumor, ovarian cancer, endometrial cancer (EC) and 2 more (2 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Number of Participants with Adverse Events at 26 months and 4 more. Planned start Dec 2024; status: withdrawn.
02
Drugs
ASP1893
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)testicular cancer
Beyond the preview
Go deeper on NCT06681870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681870.